Mereo BioPharma Group (MREO) Income towards Parent Company: 2023-2025
Historic Income towards Parent Company for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$7.0 million.
- Mereo BioPharma Group's Income towards Parent Company rose 53.18% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of -$43.3 million for FY2024, which is 46.79% down from last year.
- According to the latest figures from Q3 2025, Mereo BioPharma Group's Income towards Parent Company is -$7.0 million, which was up 51.94% from -$14.6 million recorded in Q2 2025.
- In the past 5 years, Mereo BioPharma Group's Income towards Parent Company ranged from a high of -$1.8 million in Q2 2023 and a low of -$15.0 million during Q3 2024.
- Over the past 3 years, Mereo BioPharma Group's median Income towards Parent Company value was -$9.1 million (recorded in 2023), while the average stood at -$9.7 million.
- Per our database at Business Quant, Mereo BioPharma Group's Income towards Parent Company tumbled by 599.89% in 2024 and then soared by 53.18% in 2025.
- Over the past 3 years, Mereo BioPharma Group's Income towards Parent Company (Quarterly) stood at -$9.1 million in 2023, then grew by 22.65% to -$7.0 million in 2024, then skyrocketed by 53.18% to -$7.0 million in 2025.
- Its last three reported values are -$7.0 million in Q3 2025, -$14.6 million for Q2 2025, and -$12.9 million during Q1 2025.